"Tanycyte-Based Platform for Investigating Brain Uptake of Metabolic Peptides and Drugs"


The T-GATE project (2025-2027) aims to develop an in vitro human tanycyte barrier model for investigations of brain entry of neuropeptides as well as peptide therapeutics.

The team will create a baseline model using mouse tanycytes and transition to human stem cell-derived tanycytes for peptide transport in a system nearer human physiology. The team's in vitro barrier model enables high-throughput screening of barrier-penetrating compounds, offering a novel brain entry route for metabolic and CNS therapies. The expected outcome of the T-GATE project is to provide robust screening tools and open-access knowledge for broader drug discovery.

This page will be regularly updated as the T-GATE project progresses. You are always welcome to reach out to the team, if you are interested in learning more about the project.


THE T-GATE TEAM


Academic team members

Industrial team member

  • Anja Mosekjær Bengtsson, Gubra

"The T-GATE project will advance our understanding of tanycyte-mediated transport mechanisms at the blood-brain interface, bridging fundamental neuroscience with translational drug discovery. We are happy to have gathered a world-class team for the task, consisting of outstanding PI’s with complementing expertise. ODIN provides the ideal platform for this work, fostering collaboration between academic excellence and industry expertise to develop innovative CNS-targeted therapeutics."

 

Birger Brodin, Head of the T-GATE project


T-GATE INDUSTRY PARTNER

Gubra is a contract research organisation (CRO) and biotech company specialized in preclinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. You can read more about Gubra via the link below.

"At Gubra, we are committed to advancing translational models for metabolic and CNS disorders, and this partnership provides a unique opportunity to develop high-impact, human-relevant in vitro systems.

The T-GATE collaboration through ODIN bridges academic innovation with industry expertise, accelerating the development of human-relevant models for CNS and metabolic disorders. At Gubra, we see this as a key opportunity to advance translational drug discovery and novel therapeutic strategies."

 

Anja Mosekjær Bengtsson, Gubra A/S,


 

"The T-GATE project is a unique opportunity to apply cutting-edge imaging technologies to unravel complex subcellular transport mechanisms at the tanycyte barrier.

By leveraging advanced microscopy and human stem cell modelling, we can visualize polarized peptide and drug transport in unprecedented detail. This collaboration combines world-class expertise in barrier biology, pharmacology, and imaging, making it a powerful platform for breakthrough discoveries in CNS drug delivery."

 

Morten Schallburg Nielsen, Professor, Aarhus University

 


ABOUT ODIN

We unite bright minds from industry and academia to jointly create need-driven clinical research projects - and pave the way for innovative new treatments and diagnostics. We fund the best project ideas through competitive funding calls. Although companies cannot receive funding, it is free of charge to join.

The platform is sponsored by the Novo Nordisk Foundation with 180 million DKK from 2024-2029.

CONTACT ODIN

You are welcome to contact us if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.

Although the platform spans five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 120, blg 1521-214.